Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607244 | 0.86 | L3MBTL1 (0.60) | L3MBTL1PARP1IP6K1KDM4EALDH1A1 | |
| SCHEMBL7600132 | 0.86 | L3MBTL1 (0.60) | L3MBTL1PARP1IP6K1KDM4EALDH1A1 | |
| SCHEMBL12177224 | 0.81 | L3MBTL1 (0.48) | L3MBTL1PARP1IP6K1KDM4EALDH1A1 | |
| SCHEMBL30186355 | 0.81 | ESR1 (0.62) | L3MBTL1IP6K1KDM4EALDH1A1HPGD | |
| SCHEMBL1500289 | 0.81 | L3MBTL1 (0.48) | L3MBTL1IP6K1KDM4EALDH1A1HPGD | |
| SCHEMBL9919057 | 0.81 | F2RL3 (0.51) | L3MBTL1IP6K1KDM4EALDH1A1ACVR1 | |
| SCHEMBL5312155 | 0.81 | L3MBTL1 (0.48) | L3MBTL1IP6K1KDM4EALDH1A1HPGD | |
| SCHEMBL25949932 | 0.79 | HTR1A (0.42) | L3MBTL1CHEK1PARP1PIM1RPS6KA3 | |
| SCHEMBL13267232 | 0.78 | USP5 (0.46) | CHEK1PARP1PIM1RPS6KA3KDM4E | |
| SCHEMBL25111597 | 0.78 | L3MBTL1 (0.46) | L3MBTL1IP6K1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023091747-A1 | MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2021242923-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-9199937-B2 | Substituted quinolines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150065489-A1 | Substituted Quinolines and Their Use As Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2015-03-05 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013014060-A1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010039535-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | META COSMETICS, LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | L3MBTL1 245/4885CHEK1 2176/4885PARP1 768/4885 |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | L3MBTL1 3448/4885CHEK1 2336/4885PARP1 2722/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | L3MBTL1 4663/4885CHEK1 4687/4885PARP1 4246/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | L3MBTL1 4538/4885CHEK1 4488/4885PARP1 830/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | L3MBTL1 3523/4885CHEK1 2187/4885PARP1 2676/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | L3MBTL1 3523/4885CHEK1 2187/4885PARP1 2676/4885 |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | L3MBTL1 1527/4885CHEK1 3270/4885PARP1 1686/4885 |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PTAFR, ADGRF1, P2RY6 | L3MBTL1 4704/4885CHEK1 4645/4885PARP1 1681/4885 |
| US-20150065489-A1 | Substituted Quinolines and Their Use As Medicaments | QARS1, RECQL, CYP3A7 | L3MBTL1 4455/4885CHEK1 1923/4885PARP1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.